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Abstract
The melanocortin-2-receptor (MC2R), also known as the ACTH receptor, is a critical 
component of the hypothalamic–pituitary–adrenal axis. The importance of MC2R in 
adrenal physiology is exemplified by the condition familial glucocorticoid deficiency (FGD), 
a potentially fatal disease characterised by isolated cortisol deficiency. MC2R mutations 
cause ~25% of cases. The discovery of a MC2R accessory protein MRAP, mutations of which 
account for ~20% of FGD, has provided insight into MC2R trafficking and signalling. MRAP 
is a single transmembrane domain accessory protein highly expressed in the adrenal 
gland and essential for MC2R expression and function. Mouse models helped elucidate the 
action of ACTH. The Mc2r-knockout (Mc2r−/−) mice was the first mouse model developed 
to have adrenal insufficiency with deficiencies in glucocorticoid, mineralocorticoid and 
catecholamines. We recently reported the generation of the Mrap−/− mice which better 
mimics the human FGD phenotype with isolated glucocorticoid deficiency alone. The 
adrenal glands of adult Mrap−/− mice were grossly dysmorphic with a thickened capsule, 
deranged zonation and deranged WNT4/beta-catenin and sonic hedgehog (SHH) pathway 
signalling. Collectively, these mouse models of FGD highlight the importance of ACTH and 
MRAP in adrenal progenitor cell regulation, cortex maintenance and zonation.
Hypothalamo–pituitary–adrenal axis
The hypothalamo–pituitary–adrenal (HPA) axis dictates 
the production of glucocorticoids secreted from the 
adrenal gland. Parvocellular neurosecretory neurons 
within the hypothalamic paraventricular nucleus (PVN) 
secrete corticotropin-releasing hormone (CRH) and 
arginine vasopressin (AVP) (1) into the hypophyseal portal 
circulation, and these act on anterior pituitary corticotroph 
cells to trigger secretion of adrenocorticotropic hormone 
(ACTH) (2, 3). ACTH, a 39 amino acid peptide, is produced 
by cleavage of its precursor protein, pro-opiomelanocortin 
(POMC). Other cleavage products of POMC include α-, β-, 
γ-melanocyte-stimulating hormones (MSH), β-endorphin, 
N-terminal peptide of pro-opiomelanocortin, lipotrophins 
and Met-enkephalin, corticotropin-like intermediate 
peptide (CLIP) (reviewed in 4, 5). ACTH is released into 
the circulation to act on peripheral sites, mainly the 
adrenal glands to stimulate glucocorticoid hormone 
production. Glucocorticoids have a negative feedback 
on the release of CRH and AVP at the hypothalamus and 
ACTH at the pituitary, thus providing tight regulation of 
cortisol production.
ACTH receptor/melanocortin-2-receptor
The ACTH receptor (also known as the melanocortin-
2-receptor (MC2R)), cloned in 1992 (6), is a critical 
component of the HPA axis and a member of the 
melanocortin receptor family. Other members are MC1R, 
MC3R, MC4R and MC5R – the functions of which were 
recently reviewed elsewhere (4). MC2R is unique in that it 
only binds ACTH, whereas MC1R, MC3R, MC4R and MC5R 
-19-0190
Key Words
 f ACTH
 f MRAP
 f adrenal
 f stem cells
 f MC2R
Endocrine Connections
(2019) 8, R122–R130
ID: 19-0190
8 7
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-19-0190
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 08/19/2019 02:26:11PM
via Queen Mary University of London
T V Novoselova et al. ACTH signalling R123
PB–R9
8:7
bind the melanocortins α-MSH,β-MSH and γ-MSH. In the 
adrenal gland, MC2R is expressed in all zones of the adrenal 
cortex. Its principal site of action is the zona fasciculata 
(ZF) in the generation of glucocorticoids in response to 
ACTH, although action on the zona glomerulosa (ZG) and 
zona reticularis (ZR) have been implicated in a number of 
physiological and disease states (7). In the case of the ZG, 
ACTH can acutely stimulate aldosterone production and 
there is now growing interest in the role of ACTH/MC2R 
in primary hyperaldosteronism (8, 9).
ACTH resistance syndromes and FGD
Much of what we know about MC2R has been through 
the study of the ACTH resistance syndrome, FGD. FGD is a 
rare autosomal recessive condition clinically characterised 
by isolated glucocorticoid deficiency in the presence of 
normal mineralocorticoid function. FGD was first reported 
in two siblings diagnosed with Addison’s disease without 
hypoaldosteronism (10). Patients with FGD usually 
present in the neonatal period or early childhood with 
symptoms of hypocortisolaemia such as hypoglycaemia, 
failure to thrive, recurrent infections, collapse and 
seizures along with severe hyperpigmentation due to the 
extra-adrenal action of excessive plasma ACTH on MC1R 
in the skin melanocytes (11). Biochemically, FGD patients 
present with very high plasma ACTH levels often greater 
than 1000 pg/mL paired with very low or absent serum 
cortisol concentrations, hence the term ACTH resistance. 
Aldosterone levels are usually unaffected although 
derangements have been reported in a subset of patients 
(11, 12, 13). With the identification of additional FGD 
causative genes such as steroidogenic acute regulatory 
protein (STAR), minichromosome maintenance 4 
(MCM4), nicotinamide nucleotide transhydrogenase 
(NNT), thioredoxin reductase 2 (TXNRD2), cytochrome 
p450scc (CYP11A1), glutathione peroxidase 1 (GPX1), 
peroxiredoxin 3 (PRDX3) and sphingosine 1-phosphate 
lyase (SGPL1), additional phenotypes including 
permanent or evolving mineralocorticoid deficiency 
have been reported, which has been recently reviewed 
elsewhere (14).
Loss-of-function mutations in MC2R and FGD 
type 1
The first loss-of-function missense mutation in MC2R, S74I, 
was identified in 1993 after candidate-gene sequencing 
of two siblings with FGD (15). Following this, numerous 
loss-of-function mutations have been identified scattered 
along the whole receptor (16), cementing the importance 
of MC2R in HPA biology. MC2R gene mutations account 
for approximately 25% of all FGD cases (17, 18) and are 
referred to as FGD type I (OMIM#202200). The majority 
of missense mutations result in a misfolded protein and 
its retention in the endoplasmic reticulum while some 
genetic defects affect ligand binding, signal transduction 
or lead to a truncated protein product (4, 19). Patients 
harbouring MC2R mutations have been shown to have tall 
stature (16, 20, 21, 22) along with advanced or dissociated 
bone age (23). The mechanism for this phenomenon 
remains unclear but is not due to the insulin-like growth 
factor 1–growth hormone axis as this is normal (20). One 
potential explanation is that the phenotype is due to 
high plasma ACTH levels acting on MCRs in bone (24, 
25). In support of this, ACTH has been shown to directly 
increase chondroprogenitor cell proliferation in vitro (26) 
and promote chondrocyte differentiation although the 
target MCR responsible for this action is uncertain (24). 
Interestingly, growth velocity falls after the introduction 
of glucocorticoid replacement, during which plasma 
ACTH levels often remain high. Another clinical 
feature, absent adrenarche, has also been described (27) 
and, in conjunction with findings that have linked 
polymorphisms in MC2R with age of onset of adrenarche, 
highlights the importance of ACTH in the regulation of 
adrenarche in children (28). The adrenal glands have been 
reported to be small in FGD, with histopathology showing 
the absence of fasciculata or reticularis cells together 
with disorganisation of zona granulosa (ZG) cells (16). 
Recent data in mouse models show that PKA signalling 
overactivation drives the differentiation of a reticularis-
like zone in mice, supportive of the importance of ACTH 
in adrenal androgen regulation (29).
Melanocortin-2-receptor accessory protein 
(MRAP) mutations and FGD type 2
Genetic studies of FGD patients with a normal MC2R 
identified variants in the C21orf61 gene. These variants 
would result in a truncation or complete absence of the 
protein product, which was found to be highly expressed 
in the adrenal gland and adipose tissue (17). In vitro 
studies revealed that this protein interacted with MC2R 
and was the adrenal specific factor necessary for the 
transport of the receptor to the plasma membrane and 
for receptor signalling (17, 30, 31, 32). The protein was 
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therefore renamed melanocortin 2 receptor accessory 
protein (MRAP). It is now known that mutations in MRAP 
cause approximately 20% of all FGD cases and these are 
termed FGD type 2 (33, 34). In comparison with FGD 
type 1, patients with MRAP mutations present earlier 
with more severe disease. Tall stature is not seen, which is 
probably a reflection of commencement of glucocorticoid 
replacement at an earlier age (21). To date, two FGD type 
2 patients have been reported as requiring fludrocortisone 
treatment, although it is unclear if this is a transient 
phenomenon (35).
MRAP is a single transmembrane domain protein 
which is highly evolutionarily conserved in the 
N-terminal and transmembrane regions (17). Human 
MRAP has two isoforms produced by alternative splicing, 
MRAP-α (19 kDa) and MRAP-β (11.5 kDa), which differ 
in the C-terminus. The functional difference between 
the two isoforms is unclear although differences have 
been reported in ACTH-binding capacity and cAMP 
generation (36). Interestingly, MRAP can form unique 
antiparallel transmembrane homodimers, which together 
with its paralogue MRAP2 are as yet the only group of 
proteins known to do so in eukaryotic cells. These MRAP 
homodimers form multimers with MC2R (37, 38, 39). The 
orientation of the dimers is critical to function (37, 38, 
39); moreover, these antiparallel homodimers are made 
early on in the biogenesis of the protein, are maintained 
and stable, and in a heterologous cell based system have 
a half-life of 2 h (40). Although MRAP in vitro binds and 
modulates the function of other MCRs (30), it is unclear 
what physiological relevance this has at present.
Mouse models of FGD
The first mouse model of FGD was generated by Chida 
et  al. in 2007 (41). The Mc2r KO mouse model was the 
last member of the melanocortin receptor family to 
be knocked out in mice. We recently generated a novel 
Mrap KO mouse model which, like FGD, has isolated 
glucocorticoid deficiency. Both models are discussed in 
more detail below.
Mc2r-knockout mouse model
A mouse model of MC2R deficiency was generated 
by replacing the whole coding region of Mc2r with 
a neomycin-resistance gene cassette (41), leading to 
complete absence of Mc2r transcript in Mc2r−/− mice. 
On a C57BL/6J background, the majority of Mc2r−/− 
mice did not survive 48 h after birth. Genotyping of 129 
living mice at 4 weeks of age identified that only 9 (7%) 
were Mc2r−/−. It is worth noting that on a B6/Balbc mix 
background approximately half Mc2r−/− mice survived 
to adulthood, suggesting genetic modifiers at play (42). 
Detailed analysis demonstrated that Mc2r−/− mice failed 
to produce glucocorticoids and developed profound 
neonatal hypoglycaemia resulting in high mortality 
levels during the first days of life. Moreover, pups born 
to homozygous Mc2r-null parents died before postnatal 
day 0.5 due to lung failure, highlighting the importance 
of glucocorticoids in foetal lung maturation (41). In 
addition to glucocorticoid deficiency, Mc2r−/− mice 
also had significantly lower serum levels of aldosterone 
and catecholamines (41). Epinephrine levels were 
significantly reduced in Mc2r−/− animals, whilst dopamine 
and norepinephrine concentrations were unchanged. 
Examination of the adrenals of surviving adult mice 
(never replaced with glucocorticoids) revealed dysmorphic 
glands with gross hypoplasia of the ZF. Moreover, lipid 
droplets within the ZF cells were markedly reduced or 
absent, but cell nuclei were normal. However, the precise 
cell identity of such ‘ZF’ cells is not known. Interestingly, 
the adrenal capsule in the Mc2r-null mice was thickened 
compared to Mc2r+/+ littermates. The majority of naturally 
occurring MC2R loss-of-function mutations are missense 
mutations, many with residual function (4, 19). Location 
and type of reported MC2R mutations are summarised in 
a recent review (4). As a demonstration of this, patients 
with missense MC2R mutations have been known 
to present later on in childhood (21). Several more 
severe cases including homozygous nonsense or frame 
shift mutations in MC2R have been described to have 
hyponatraemia and/or disruption of renin-angiotensin-
aldosterone system (12, 13, 35). The majority of these are 
transient though permanent fludrocortisone replacement 
has been described in several children (35). Hence, 
although the complete KO of Mc2r in mice is not fully 
representative of human FGD type 1, the model has 
nevertheless highlighted crucial actions of ACTH and/or 
glucocorticoids during development.
Mrap-knockout mouse model
We recently reported a Mrap KO (Mrap−/−) mouse model 
created by targeting the first coding exon of Mrap, 
which led to complete absence of transcript and protein 
in homozygote mice (43). Intercrossing heterozygote 
(Mrap+/−), also on a C57BL/6J background, demonstrated 
high neonatal mortality. Out of 325 mice generated from 
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breeding Mrap+/− mice, only three Mrap−/− mice (<1%) 
survived until weaning (43). The new-born pups born 
from heterozygous parents with normal adrenal function 
died before postnatal day 1 and morphologically showed 
immature lungs and lack of hepatic glycogen stores (43). 
Glucocorticoid treatment of pregnant Mrap+/− dams 
rescued the phenotype, resulting in Mrap−/− mice born at 
the expected ratio of 25%. This indicated that the observed 
high mortality in homozygous Mrap−/− newborns was 
likely to be due to glucocorticoid deficiency rather than 
a direct effect of Mrap deletion. Moreover, this phenotype 
highlights the importance of foetal rather than maternal 
glucocorticoids in pre-partum neonatal adaptation in the 
Mrap−/− mouse.
The severity of this phenotype is consistent with the 
human data whereby FGD type 2 patients present soon 
after birth (21), thought to be due to the severity of the 
mutations in MRAP that lead to complete disruption or 
absence of protein (21). Naturally occurring mutations 
in MRAP (location and type) have recently been 
reviewed (4).
Adult Mrap−/− mice of both genders exhibited a grossly 
dysmorphic adrenal cortex with the glucocorticoid 
synthesis pathway severely downregulated and unable to 
produce glucocorticoids in the presence of high plasma 
ACTH levels. Surprisingly, unlike the Mc2r−/− mice, 
circulating aldosterone and catecholamine levels were 
unaffected (41, 43). The enzyme phenylethanolamine 
N-methyltransferase (PNMT), which is responsible for 
conversion of norepinephrine to epinephrine, appeared 
to be unaffected in Mrap−/− mice even though PNMT 
expression is known to be dependent on glucocorticoid 
action. In contrast, PNMT is markedly reduced in 
Mc2r−/− (41). As both knockout models are on a C57BL/6J 
background, one obvious difference is that the Mrap−/− 
mice received relatively high doses of glucocorticoids 
between E17.5 until weaning. This could contribute to the 
discrepancy in PNMT between Mc2r−/− and Mrap−/− mice, 
especially in light of the fact that prenatal exposure to 
glucocorticoids has been shown to lead to increased PNMT 
mRNA by RT-PCR and elevated plasma epinephrine in 
adult rats (44). The discrepancy between aldosterone levels 
in Mc2r−/− and Mrap−/− mice could be due to a number 
of possibilities, such as Mrap-independent aldosterone 
production (although in vitro the MC2R is non-functional 
in the absence of MRAP and MRAP protein expression 
closely mirrors that of MC2R in the ZG), differences in 
salt intake between the two models (both rodent lines 
are fed ad libitum on a standard chow diet although, the 
salt content may differ) and finally alterations of the 
renin–angiotensin–aldosterone system have also 
been reported in animals exposed to glucocorticoids 
prenatally (45). Determining the mechanism of such 
differences would further dissect adrenal ACTH action. 
Importantly, however, the absence of mineralocorticoid 
and catecholamine deficiency in Mrap−/− mice makes 
it a unique model for studying FGD and isolated 
glucocorticoid deficiency.
Similar to the Mc2r−/− mouse model, the Mrap−/− 
adrenal capsule is thickened, which in the Mrap−/− mice was 
shown to be due to an increased cell number, rather than 
hyperplasia. This is of particular interest as the adrenal 
capsule and the subcapsular region are known to contain 
adrenocortical stem/progenitor cells capable of dividing, 
migrating centripetally and differentiating into mature 
steroid-producing cell types (46, 47, 48). In keeping with 
this, the absence of MRAP and therefore ACTH signalling 
resulted in small adrenals with grossly deranged cortex 
zonation (discussed in subsequent sections).
Other MRAP mouse models: transgenic MRAP 
adipose tissue overexpression mouse model
Prior to its renaming in 2005, MRAP was first identified as 
a putative novel membrane protein selectively expressed 
during adipogenic conversion of 3T3-L1 cells and called 
FALP (fat tissue-specific low molecular weight protein) 
(49). The protein expressed in both brown and white fat 
tissue and highly expressed during adipogenesis (49, 50). 
More recently, the importance of MRAP in energy balance 
was demonstrated using transgenic mice overexpressing 
MRAP in a fat-specific manner, under the control of the 
aP2 (adipocyte fatty acid-binding protein) promoter (51). 
These mice were shown to be protected against diet-
induced obesity and diabetes, through enhancement of 
ACTH-induced lipolysis. Therefore, this demonstrated 
for the first time the emerging importance of MRAP 
in metabolism.
ACTH and adrenocortical renewal and 
zonation – contribution of Mrap and Mc2r KO 
mouse models
Adrenocortical renewal and regeneration
The adrenal gland has a great capacity to respond to 
changes, renew and regenerate. For example, activation 
of the HPA axis leads to expansion of the ZF and increased 
expression of CYP11B1 and glucocorticoid production, 
whilst suppression by dexamethasone leads to the 
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contraction/atrophy of the ZF, and reduced CYP11B1 and 
glucocorticoid production (52). This is not specific to the 
ZF and activation or inhibition of the renin–angiotensin–
aldosterone system (i.e. triggered by a diet low in sodium 
or treatment with ACE inhibitors, respectively) results in 
similar changes in ZG morphology, CYP11B2 expression 
and aldosterone production (53). This together with the 
appearance of compensatory growth of the contralateral 
adrenal gland following unilateral adrenalectomy (54) 
demonstrates the dynamic nature of the adrenal gland. 
Apart from remodelling, the adrenal gland can also 
regenerate from residual adrenal capsular and adherent 
ZG cells in enucleation studies (55, 56). Regeneration 
arises from cell proliferation and differentiation and is 
associated with a thickened adrenal cortex (57).
Role of ACTH in adrenal progenitor cell 
differentiation and maintenance
ACTH administration can induce ZF hyperplasia, with 
no effect on the ZG (58). More recently, the localisation 
of Mc2r and Mrap to the undifferentiated zone (layer of 
cyp11b1/b2 negative cells located between the ZG and 
ZF) in the rat adrenal (59, 60), suggested a role for ACTH 
in the differentiation of progenitor cells towards the ZF 
phenotype in vivo. However, the data from remodelling 
experiments provides somewhat conflicting evidence 
for the exact role of ACTH in adrenal progenitor cell 
differentiation and maintenance. For example, some 
studies show that treatment with dexamethasone 
blocks ZF proliferation and compensatory growth of the 
contralateral gland following unilateral adrenalectomy 
(54, 61), whilst other studies do not show this (62, 
63). Hypophysectomy, with the complete removal of 
the pituitary gland, blocks adrenal gland regeneration 
following enucleation (64) but does not completely block 
compensatory growth (52, 65), and ACTH has even been 
shown to inhibit this process (65). However, overall there 
is agreement that hypophysectomy reduces the extent 
of compensatory growth suggesting the presence of a 
pituitary factor. One possible factor is pituitary-derived 
N-POMC, derived from the POMC cleavage product pro-
γ-MSH. Neutralising antibodies against pro-γ-MSH inhibit 
both adrenal regeneration and compensatory growth. 
However, pro-γ-MSH has no direct mitogenic activity (66); 
hence, it has been suggested that further processing of pro-
γ-MSH to peptides such as N-POMC with mitogenic activity 
is required (67). Evidence of the need for pituitary factors, 
including ACTH, comes from work on POMC−/− animals 
that have complete absence of the POMC peptide (68, 69). 
POMC−/− mice have adrenal glands that fail to proliferate 
postnatally leading to atrophic adrenals which become 
undetectable with age (70). These adrenal glands from 
POMC−/− animals can be rescued in size and function, 
following transplantation into a WT recipient animal with 
physiological levels of all POMC peptides. Interestingly, 
N-POMC cannot restore adrenal growth in POMC-null 
mice (71). However, high-dose replacement of ACTH 
over several days restores POMC−/− adrenal weight, 
morphology and corticosterone secretion (68), but it has 
been suggested this is due to hypertrophy of the ZF rather 
than full regeneration of the adrenal gland (72).
Contribution of Mc2r and Mrap KO mouse models 
to understanding of adrenal stem/progenitor cell 
differentiation and maintenance
The MC2R and MRAP KO mouse models add to our 
existing knowledge of the role of ACTH in adrenal 
gland stem/progenitor cell differentiation and gland 
maintenance. Assessment of the adrenal glands of Mrap−/− 
mice at embryonic day 17.5 shows that the adrenal sizes 
are comparable to Mrap+/+ mice, derived from intercrosses 
of heterozygous mice with normal HPA activity. However, 
when assessed at 8 weeks of age the gland is significantly 
reduced in size with a thickened adrenal capsule (43). 
One major issue is the separation of the effects of absent 
ACTH action and glucocorticoid deficiency that are both 
present in adult Mrap−/− mice. After lifetime glucocorticoid 
replacement the capsule reduced in thickness but still 
remained significantly increased compared to wild-type 
littermate animals suggesting that both glucocorticoid 
deficiency and absent ACTH action contribute to the 
expansion of the stem cell niche in the adrenal gland, in 
keeping with some of the data described above. Treatment 
of WT control mice with glucocorticoid resulted in 
biochemically undetectable plasma ACTH coupled with 
corticosterone within the normal range. These mice 
have a thickened capsule and thus taken together this is 
highly suggestive that the absence of ACTH action is a key 
contributor to capsule thickening.
The Mrap−/− mouse model also introduces some novel 
concepts in the growing landscape of molecular pathways 
and factors involved in adrenal stem/progenitor cell 
determination and differentiation. In fact this field is 
rapidly gaining pace with the identification of new factors 
required for the adrenal homeostasis and zonation such as 
RSPO3, EZH2 and ZNRF3 (73, 74, 75) and (reviewed in 47, 
53). The WNT4/β-catenin and SHH pathways have been 
described to be key drivers of ZG identity (76).
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Cells that express WNT/β-catenin, which co-express 
SHH and CYP11B2, normally reside in the subcapsular 
region (41, 42, 43). It has been shown that cAMP/PKA, 
activated by ACTH signalling in the adrenal gland, 
represses the WNT/beta-catenin pathway to allow 
lineage conversion and correct adrenal cortex zonation 
(46). Consistent with this is the absence of ZF in 
the adrenals of Mrap−/− mice, whilst ZG is intact and 
functional. However, the Mrap−/− mice identifies a 
concentric zone of cells between the ZG and adrenal 
medulla that are negative for Cyp11b2, Cyp11b1 and 
20-αHSD and hence not terminally differentiated ZG, 
ZF or ZR/foetal X-zone cells respectively. These cells 
are WNT4/β-catenin positive, but negative for the 
downstream canonical targets of WNT signalling (LEF1 
and DAB2), suggesting that canonical WNT signalling 
is not active in these cells. Another option is that these 
cells were once LEF1- and DAB2-positive and have 
subsequently lost some of ZG features. The precise 
origin, fate and signalling potential of these cells are 
currently being investigated.
SHH signalling is another key pathway regulating the 
differentiation of progenitor cells into steroidogenic cells 
(77, 78). SHH-positive cells in the stem cell niche, which 
are located in the subcapsular region in mice and in the 
undifferentiated zone in rats, have been shown through 
lineage tracing to differentiate into all cortical cell 
populations in mice. The majority of SHH-descendants 
become ZG cells first and then transition to ZF cells during 
centripetal migration (48, 77). In SHH KO mice, the adrenal 
capsule is reduced to a single cell layer, suggesting that 
SHH could act as a capsule cell mitogen/chemoattractant 
for noncapsule mesenchymal cells or to maintain capsule 
progenitors (77). In the absence of MRAP, we see thickened 
capsule, upregulated SHH expression and ectopic SHH 
expression throughout the cortex, no longer restricted to 
the subscapular region. Together with the co-expression 
of WNT4 and CYP11B2, this is suggestive that these cells 
have acquired ZG features. Glucocorticoid treatment only 
partially attenuated this phenotype. Interestingly, the 
levels of Gli1, which is a canonical target of SHH, were 
unchanged despite high SHH expression. Determining 
Figure 1
Model illustrating the morphological alterations and pathway deregulation in the adrenal gland of FGD type 2. In the normal adrenal cortex, activation of 
SHH and WNT4 signalling results in driving the expression of CYP11B2, DAB2 and LEF1 leading to a zona glomerulosa (ZG) lineage. Activation of PKA due 
to the action of ACTH on MC2R/MRAP complex suppresses WNT4 resulting in inhibition of CYP11B2, DAB2 and LEF1 and differentiation into ZF cells. In 
FGD type 2 (Mrap−/− mice) adrenal glands, the lack of PKA activation results in complete absence of ZF and WNT4/SHH accumulation outside the ZG, 
where WNT4 expression in such cells do not lead to a functional ZG identity. Morphologically the ZG is expanded and is able to secrete aldosterone. The 
adrenal medulla in FGD type 2 is morphologically intact and secretes both epinephrine and norepinephrine.
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the reason for this dissociation between high SHH and 
Gli1 which is unchanged as well as the co-ordination with 
other factors involved with capsule thickness such as FGF 
signalling will be investigated in the future (Fig. 1).
In conclusion, the mouse models of FGD have 
helped elucidate the action of ACTH and glucocorticoids 
in adrenal development, progenitor cell renewal and 
zonation. Further studies will focus on the role of ACTH 
signalling in physiology as well as how this can be altered 
in disease states.
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